HOME STORY OF OUR FIRM SEARCH
ASBESTOS DRUGS POLLUTANTS ACCIDENTS MALPRACTICE
English En Français

FREE LEGAL REVIEW

First Name
Last Name
Home Phone
Work Phone
City and State
Email
Were you diagnosed with Asbestosis? Yes
Were you diagnosed with lung cancer? Yes
Were you diagnosed with Mesothelioma? yes
What is your date of diagnosis?
Additional Comments
Best time to call?

Mesothelioma Publication - Lymphohistiocytoid

This is an abstract of an article about mesothelioma and lymphohistiocytoid first published at PubMed by the NIH.

Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review.

Yao DX, Shia J, Erlandson RA, Klimstra DS.
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Ultrastruct Pathol. 2004 Jul-Aug;28(4):213-28.

Lymphohistiocytoid mesothelioma (LHM) is a term proposed to designate a variant of mesothelioma that assumes a histiocytoid morphology and contains intense lymphocytic infiltrates. Reports on this variant are few, and its clinicopathologic and ultrastructural characteristics are still to be defined. The authors have studied 4 such cases that were identified among 120 mesotheliomas in the electron microscopy (EM) files of a single institution between 1982 and 2002. Histologically, all 4 lesions were composed of diffuse proliferations of cells with a histiocytoid appearance, admixed with an intense lymphocytic infiltrate. All 4 were associated with an unequivocal sarcomatoid component. Immunohistochemical (IHC) studies showed that the majority of histiocytoid cells were positive for CD68 and vimentin in all 4 cases, suggesting fibrohistiocytic differentiation. Immunoreactivity for calretinin and AE1:AE3 was only very focally identified in 3 of 4 cases. All cases were negative for CEA (M), Leu-M1, and B72.3. The lymphocytic component in all 4 cases was almost entirely composed of CD3- and CD8-positive, small, mature T cells, with only a minor component of CD20-positive cells and occasional eosinophils. Although all cases contained numerous CD68 positive atypical cells, co-expression of CD68 and either calretinin or keratin by individual cells was difficult to demonstrate by immunohistochemistry. Ultrastructurally, 3 of the 4 cases demonstrated very focal mesothelial differentiation as evidenced by long and slender surface microvilli, including the case with negative immunoreactivity for calretinin and cytokeratin. Review of the literature yielded 6 additional LHM cases. Analysis of all 10 cases showed a male predominance (8:2) with a mean age of 58 years (31-73 years). All 10 cases involved the pleura. Three of 10 patients had known asbestos exposure. Six of 10 patients died of disease at 2-20 months after the diagnosis (mean, 6.9 months). The findings suggest that LHM is a distinct morphological variant of sarcomatoid mesothelioma for which mesothelial differentiation is difficult to document. Many of the cells composing these tumors exhibit fibrohistiocytic differentiation. The unusual morphological pattern of LHM makes a combined modality approach, including IHC, EM, and a knowledge of the clinical/radiologic findings, essential in achieving a correct diagnosis.

Exposure to asbestos is known to cause serious illnesses such as mesothelioma, asbestos-related lung cancer or asbestosis.

If you or a loved one has been diagnosed with an asbestos illness, contact our lawyers today for a free review of your case. A Weitz & Luxenberg representative will contact you as soon as possible.

Mesothelioma Mesothelioma Home Page
head Mesothelioma: An Overview
kleio The Clock Is Ticking
asbestos Our Toughest Cases
head Diagnosis
treatment Symptoms, Stages, Treatment
kleio Latest News
New York Numbers
Asbestos
Real Stories


Mesothelioma
Mesothelioma Resource Center
Mesothelioma
Information about Diagnosis
Latest News
IN THIS SECTION
Farnesyltransferase Inhibitors
Cancer Immunotherapy
Great Britain
Poland
Pemetrexed Therapy
Sv40 Specific Recall Immunity
Polish Cases
Extra Pleural Pneumonectomy
Intraoperative Radiation Therapy
Calretinin
Hyaluronan
Granulocyte Colony Stimulating Factor
Mesothelioma in Canada
Pemetrexed (Alimta)
Calretinin Antibodies
Greece
Neoplasia
FDA Pemetrexed
Secreted Frizzled Related Protein
Tumor Necrosis
Podoplanin
Lymphohistiocytoid
Mesothelioma Pathogenesis
Diagnostic Difficulties
Mesothelioma from Adenocarcinoma
Mesothelial Proliferation
ThinPrep Cytospin
Effusion
Chemotherapy Options
Heparanase
Malignant Deciduoid
Mortality
Pemetrexed in Malignant Pleural Mesothelioma
Pleural Mesothelioma
Prognostic Analysis
Italian Mortality Rates
Vinorelbine and Oxaliplatin
DNA Methylation Profiles
Primary Malignant Pericardial Mesothelioma
Abdominal CAT Scans
China
Disseminated Malignant
Statistical Validation
Pathogenesis
Lung Adenocarcinoma
Japan

Mesothelioma Lawyer

Asbestos Lawyer

Mesothelioma Attorney

Asbestos Attorney

For legal help anywhere in the U.S. call:

1 - 800 - 476 - 6070

Prior results do not guarantee a similar outcome.

ATTORNEY ADVERTISING

see also:

Malignant Deciduoid Mesothelioma Injury Publication on Malignant Deciduoid
Read an Mesothelioma Injury article about Malignant Deciduoid

Diagnostic Difficulties Mesothelioma Articles on Diagnostic Difficulties
An article about Malignant Mesothelioma and Diagnostic Difficulties

National Mesothelioma Publications The National Institute of Health mesothelioma research publications
Mesothelioma publications from the National Institute of Health